 "Anuh Pharma rallies on grant of approval of manufacturing site by WHO, Geneva")
Anuh Pharma has rallied 20% to 245 on the BSE in intra-day trade after the company said World Health Organisation (WHO) Geneva approved the manufacturing site in district Thane, Boisar, Maharashtra.
“The company’s Maharashtra site found in compliance to WHO good manufacturing practices (GMPs) for Pyrazinamide APIMF158 and Sulfadoxine APIMF234 active pharmaceutical ingredients (APIs),” Anuh Pharma said in a release.
In another filing, the company said the same facility has granted EUGMP certificate by French National Agency for Medicines and Health Products Safety (ANSM) for products Erythromycin Ethyl Succinate and Pyrazinamide.
At 01:38 pm; the stock was up 13% at Rs 231, the top gainer among the S&P BSE Smallcap index. Around 130,000 shares changed hands on the counter against an average 2,844 shares that were traded daily in past two weeks on the BSE.
“The company’s Maharashtra site found in compliance to WHO good manufacturing practices (GMPs) for Pyrazinamide APIMF158 and Sulfadoxine APIMF234 active pharmaceutical ingredients (APIs),” Anuh Pharma said in a release.
In another filing, the company said the same facility has granted EUGMP certificate by French National Agency for Medicines and Health Products Safety (ANSM) for products Erythromycin Ethyl Succinate and Pyrazinamide.
At 01:38 pm; the stock was up 13% at Rs 231, the top gainer among the S&P BSE Smallcap index. Around 130,000 shares changed hands on the counter against an average 2,844 shares that were traded daily in past two weeks on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%